Generation and Evaluation of Pharmacologically Relevant Drug–Drug Cocrystal for Gout Therapy
- 18 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 20 (6) , 3577-3583
Abstract
No abstract availableKeywords
Funding Information
- Council of Scientific and Industrial Research (02(0223)/15/EMR-II)
- University Grants Commission
- Anusandhan National Research Foundation (EMR/2015/002075, SR/S2/JCB-06/2009)
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
This publication has 28 references indexed in Scilit:
- Piroxicam–clonixin drug–drug cocrystal solvates with enhanced hydration stabilityCrystEngComm, 2019
- Combination urate-lowering therapy in the treatment of gout: What is the evidence?Seminars in Arthritis and Rheumatism, 2019
- Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and ApplicationsCrystal Growth & Design, 2018
- Development of dual drug loaded solid self microemulsifying drug delivery system: Exploring interfacial interactions using QbD coupled risk based approachJournal of Molecular Liquids, 2017
- Co-crystal of Tramadol Hydrochloride–Celecoxib (ctc): A Novel API–API Co-crystal for the Treatment of PainCrystal Growth & Design, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of FebuxostatClinical Pharmacokinetics, 2016
- Multidrug co-crystals: towards the development of effective therapeutic hybridsDrug Discovery Today, 2016
- Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approachDrug Delivery and Translational Research, 2015
- Prophylaxis for acute gout flares after initiation of urate-lowering therapyRheumatology, 2014
- Drug-drug co-crystalsDARU Journal of Pharmaceutical Sciences, 2012